Director/PDMR Shareholding

PureTech Health PLC

27 June 2024

 

27 June 2024

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces the sale of certain shares by members of executive management and non-executive directors ("PDMRs") pursuant to its recently completed Tender Offer.

The Company's total issued ordinary share capital is 257,927,489 shares, 18,608,909 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Eric Elenko John LaMattina Robert Langer
2	Reason for the notification
a)	Position/status	Eric Elenko: President John LaMattina: Non-Executive Director Robert Langer: Non-Executive Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Sale of ordinary shares pursuant to Company's recently completed Tender Offer.
c)	Price(s) and volume(s)	Individual Price Volume Eric Elenko 2.50 GBP 479,553 ordinary shares John LaMattina 2.50 GBP 54,882 ordinary shares Robert Langer 2.50 GBP 233,098 ordinary shares
e)	Date of the transaction	24 June 2024
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

 

END